Peddock Capital Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $402K | Hold |
2,632
| – | – | 0.09% | 120 |
|
|
2025
Q4 | $363K | Hold |
2,632
| – | – | 0.08% | 123 |
|
|
2025
Q3 | $338K | Hold |
2,632
| – | – | 0.07% | 124 |
|
|
2025
Q2 | $318K | Sell |
2,632
-550
| -17% | -$62K | 0.07% | 127 |
|
|
2025
Q1 | $355K | Buy |
3,182
+58
| +2% | +$6.17K | 0.09% | 119 |
|
|
2024
Q4 | $304K | Hold |
3,124
| – | – | 0.07% | 132 |
|
|
2024
Q3 | $359K | Hold |
3,124
| – | – | 0.09% | 123 |
|
|
2024
Q2 | $333K | Hold |
3,124
| – | – | 0.09% | 120 |
|
|
2024
Q1 | $302K | Hold |
3,124
| – | – | 0.08% | 131 |
|
|
2023
Q4 | $315K | Hold |
3,124
| – | – | 0.1% | 122 |
|
|
2023
Q3 | $318K | Hold |
3,124
| – | – | 0.11% | 118 |
|
|
2023
Q2 | $315K | Hold |
3,124
| – | – | 0.1% | 119 |
|
|
2023
Q1 | $287K | Hold |
3,124
| – | – | 0.1% | 127 |
|
|
2022
Q4 | $283K | Hold |
3,124
| – | – | 0.11% | 125 |
|
|
2022
Q3 | $237K | Hold |
3,124
| – | – | 0.1% | 138 |
|
|
2022
Q2 | $264K | Hold |
3,124
| – | – | 0.1% | 132 |
|
|
2022
Q1 | $274K | Hold |
3,124
| – | – | 0.09% | 137 |
|
|
2021
Q4 | $273K | Hold |
3,124
| – | – | 0.09% | 126 |
|
|
2021
Q3 | $255K | Buy |
3,124
+13
| +0.4% | +$1.17K | 0.09% | 123 |
|
|
2021
Q2 | $287K | Hold |
3,111
| – | – | 0.1% | 120 |
|
|
2021
Q1 | $266K | Hold |
3,111
| – | – | 0.1% | 123 |
|
|
2020
Q4 | $294K | Buy |
3,111
+115
| +4% | +$10K | 0.15% | 93 |
|
|
2020
Q3 | $261K | Hold |
2,996
| – | – | 0.16% | 93 |
|
|
2020
Q2 | $262K | Hold |
2,996
| – | – | 0.17% | 90 |
|
|
2020
Q1 | $247K | Hold |
2,996
| – | – | 0.18% | 86 |
|
|
2019
Q4 | $284K | Hold |
2,996
| – | – | 0.15% | 94 |
|
|
2019
Q3 | $260K | Hold |
2,996
| – | – | 0.14% | 95 |
|
|
2019
Q2 | $274K | Sell |
2,996
-348
| -10% | -$29.5K | 0.15% | 90 |
|
|
2019
Q1 | $288K | Hold |
3,344
| – | – | 0.16% | 86 |
|
|
2018
Q4 | $257K | Buy |
3,344
+190
| +6% | +$14.8K | 0.15% | 89 |
|
|
2018
Q3 | $243K | Hold |
3,154
| – | – | 0.12% | 107 |
|
|
2018
Q2 | $213K | Sell |
3,154
-19
| -0.6% | -$1.31K | 0.11% | 115 |
|
|
2018
Q1 | $230K | Hold |
3,173
| – | – | 0.12% | 107 |
|
|
2017
Q4 | $239K | Hold |
3,173
| – | – | 0.12% | 109 |
|
|
2017
Q3 | $244K | Sell |
3,173
-496
| -14% | -$37.5K | 0.13% | 104 |
|
|
2017
Q2 | $274K | Buy |
3,669
+1
| +0% | +$71 | 0.15% | 98 |
|
|
2017
Q1 | $244K | Buy |
3,668
+514
| +16% | +$34.3K | 0.14% | 94 |
|
|
2016
Q4 | $206K | Buy |
3,154
+502
| +19% | +$32.6K | 0.12% | 97 |
|
|
2016
Q3 | $188K | Buy |
+2,652
| New | +$193K | 0.12% | 99 |
|
Other funds holding NVS
Peddock Capital Advisors's NVS Position: Q1 2026 in Review
Peddock Capital Advisors held its Novartis (NVS) position steady in Q1 2026 at 2,632 shares worth $402K. The position accounts for 0.09% of the portfolio, ranked #120.
Peddock Capital Advisors first reported a position in NVS in Q3 2016 and has held it in 39 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Peddock Capital Advisors held 2,632 shares of Novartis worth $402K as of Q1 2026.
- Peddock Capital Advisors left its Novartis share count unchanged in Q1 2026.
- Novartis made up 0.09% of Peddock Capital Advisors's portfolio in Q1 2026, its #120 holding.
- Peddock Capital Advisors first reported a position in Novartis in Q3 2016 and has held it in 39 quarters since.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Peddock Capital Advisors's 13F filing for Q1 2026, filed 15 Apr 2026.